Sheeva Talebian
Reproductive Endocrinologist
CCRM New York
- Sharing the role of technology and partnerships in the design & recruitment of studies.
- Highlighting adaptive trial designs, decentralized models, and inclusive recruitment strategies.
- Exploring how smarter trial design accelerates approval, reduces risk, and improves real-world outcomes.
- Discover how real-world data, genomics, and AI are revealing new targets and mechanisms in female-specific and reproductive conditions.
- Learn how data integration is shortening timelines from target identification to preclinical validation.
- Sharing insights into novel drug discovery approaches, the use of AI, multi-omics data, and 3D models.
Reproductive Health
Drug Development
Stasa Stankovic
Chief Executive Officer
OvartiX
Mark Eccleston
Chief Executive Officer
ValiRx
- Explore the mechanism of action and preclinical efficacy of a first-in-class oncolytic peptide targeting triple negative breast cancer (TNBC).
- Understand how peptide-based approaches offer new hope for aggressive and treatment-refractory subtypes of breast cancer.
- Learn about the breast cancer therapeutic roadmap and landscape.
Oncology
Drug Development
Mark Eccleston
Chief Executive Officer
ValiRx
Oliver Bates
Chief Executive Officer
Viramal
Leveraging tech and epidemiological data to reduce diagnostic delays in reproductive health.
Exploring AI, biomarkers, digital therapeutics, and digital platforms that enable earlier and more accurate diagnoses.
Advice to start-ups and sharing the market opportunity for clinical integration in preventative & diagnostic women’s health
Drug Development
Miller Morris
CEO
Comma
Sheeva Talebian
Reproductive Endocrinologist
CCRM New York
Anna Mamo
Director, Translational Sciences
UPMC
Carrie Nixon
Founder & CEO
Nixon Law Group